Revenue Update on Medivation Inc(NASDAQ:MDVN)

Medivation Inc(NASDAQ:MDVN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $206.16M. Analysts estimated a revenue of $212.74M. Earnings per share were $0.29. Analysts had estimated an EPS of $0.27.

Medivation Inc (MDVN) made into the market gainers list on Wednesdays trading session with the shares advancing 1.94% or 1.265 points. Due to strong positive momentum, the stock ended at $66.48, which is also near the day’s high of $68.37. The stock began the session at $65.07 and the volume stood at 25,76,025 shares. The 52-week high of the shares is $68.37 and the 52 week low is $26.41. The company has a current market capitalization of $11,031 M and it has 16,59,28,670 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Andrew Kenneth William Powell (SVP, General Counsel & Crp Sec) sold 2,578 shares at $60.42 per share price.Also, On May 9, 2016, Rick Bierly (CFO (former) sold 10,340 shares at $59.98 per share price.On Mar 16, 2016, Dawn Svoronos (director) sold 6,000 shares at $38.90 per share price, according to the Form-4 filing with the securities and exchange commission.

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *